TUDORZA PRESSAIR Drug Patent Profile

Which patents cover Tudorza Pressair, and when can generic versions of Tudorza Pressair launch?

Tudorza Pressair is a drug marketed by Azurity and is included in one NDA. There are two patents protecting this drug.

This drug has seventy-two patent family members in thirty-six countries.

The generic ingredient in TUDORZA PRESSAIR is aclidinium bromide. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the aclidinium bromide profile page.

DrugPatentWatch^® Generic Entry Outlook for Tudorza Pressair

Tudorza Pressair was eligible for patent challenges on July 23, 2016.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 13, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for TUDORZA PRESSAIR

International Patents:	72
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	59
Patent Applications:	436
Drug Prices:	Drug price information for TUDORZA PRESSAIR
What excipients (inactive ingredients) are in TUDORZA PRESSAIR?	TUDORZA PRESSAIR excipients list
DailyMed Link:	TUDORZA PRESSAIR at DailyMed

See drug prices for TUDORZA PRESSAIR

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TUDORZA PRESSAIR

NDA:

202450

Dosage:

POWDER, METERED;INHALATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for TUDORZA PRESSAIR

Drug Class	Anticholinergic
Mechanism of Action	Cholinergic Antagonists

US Patents and Regulatory Information for TUDORZA PRESSAIR

TUDORZA PRESSAIR is protected by two US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Azurity	TUDORZA PRESSAIR	aclidinium bromide	POWDER, METERED;INHALATION	202450-001	Jul 23, 2012		RX	Yes	Yes			Y
Azurity	TUDORZA PRESSAIR	aclidinium bromide	POWDER, METERED;INHALATION	202450-001	Jul 23, 2012		RX	Yes	Yes			Y

Expired US Patents for TUDORZA PRESSAIR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Azurity	TUDORZA PRESSAIR	aclidinium bromide	POWDER, METERED;INHALATION	202450-001	Jul 23, 2012
Azurity	TUDORZA PRESSAIR	aclidinium bromide	POWDER, METERED;INHALATION	202450-001	Jul 23, 2012
Azurity	TUDORZA PRESSAIR	aclidinium bromide	POWDER, METERED;INHALATION	202450-001	Jul 23, 2012
Azurity	TUDORZA PRESSAIR	aclidinium bromide	POWDER, METERED;INHALATION	202450-001	Jul 23, 2012

EU/EMA Drug Approvals for TUDORZA PRESSAIR

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Covis Pharma Europe B.V.	Bretaris Genuair	aclidinium bromide	EMEA/H/C/002706Bretaris Genuair is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).	Authorised	no	no	no	2012-07-20
Covis Pharma Europe B.V.	Eklira Genuair	aclidinium bromide	EMEA/H/C/002211Eklira Genuair is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).	Authorised	no	no	no	2012-07-20

International Patents for TUDORZA PRESSAIR

When does loss-of-exclusivity occur for TUDORZA PRESSAIR?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Cyprus

Denmark

Ecuador

European Patent Office

Finland

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Montenegro

New Zealand

Peru

Poland

Portugal

Russian Federation

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TUDORZA PRESSAIR around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	029760	DERIVADOS DE QUINUCLIDINA, PROCESO PARA PREPARAR DICHOS DERIVADOS, COMPUESTOS INTERMEDIARIOS UTILIZABLES EN DICHO PROCESO, COMPOSICIONES FARMACEUTICAS FORMULADAS CON DICHOS DERIVADOS Y USO DE DICHOS DERIVADOS PARA LA PRODUCCION DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES RESPIRATORIAS, URINA
Austria	235492
Australia	2005202144
Australia	6433000

Supplementary Protection Certificates for TUDORZA PRESSAIR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1200431	C300573	Netherlands		PRODUCT NAME: ACLIDINIUMZOUT MET EEN FARMACEUTISCH AANVAARDBAAR ANION VAN EEN EEN- OF MEERWAARDIG ZUUR, IN HET BIJZONDER ACLIDINIUMBROMIDE; REGISTRATION NO/DATE: EU/1/12/778/001-003EU/1/12/781/001-003 2012200720
1200431	CA 2013 00002	Denmark
1200431	PA2013001	Lithuania		PRODUCT NAME: ACLIDINII BROMIDUM; REGISTRATION NO/DATE: EU/1/12/778/001 - EU/1/12/778/003, 2012 07 20 EU/1/12/781/001 - EU/1/12/781/003 20120720
1200431	92132	Luxembourg		PRODUCT NAME: SEL D ACLIDINIUM AVEC ANION D UN ACIDE MONO OU POLYVALENT PHARMACEUTIQUEMENT ACCEPTABLE PARTICULIEREMENT LE BROMURE D ACLIDINIUM

Tudorza Pressair (aclidinium bromide) Market Dynamics and Financial Trajectory: Sales, Pricing, Competition, and Exclusivity-Driven Risk

Last updated: July 28, 2026

Executive summary: Tudorza Pressair (aclidinium bromide) built a share position in US COPD maintenance after launch in 2012, but its financial trajectory has been pressured by long-acting muscarinic antagonist (LAMA) competition, evolving treatment preferences toward once-daily LAMAs and LAMA/LABA fixed-dose combinations, and channel pricing moves by brands in the class. From a patent and exclusivity standpoint, the risk profile is more about line extensions and formulation/label patents than broad platform exclusivity, with generic entry dynamics historically centered on US Orange Book patent cliffs rather than biologic-style biosimilar transitions.

What are the historical sales trends for Tudorza Pressair (aclidinium bromide) in the US?

Answer: Tudorza Pressair is a mid-tier COPD brand in US respiratory, with peak years early in the launch window followed by plateauing and share erosion as competing LAMAs and LAMA/LABA combinations expanded formularies.

Sales trajectory: launch, peak, and erosion pattern

Key market dynamics that shaped revenue over time:

• Therapeutic category shift: COPD maintenance treatment increasingly favored once-daily dosing convenience, which is structurally advantaged versus twice-daily regimens.
• Formulary evolution: Managed-care formularies tightened place-in-therapy controls, often steering patients to the lowest net-cost option among comparable LAMAs and LAMA/LABA products.
• Class competition: Multiple LAMAs with stronger payer footprints gained market share as evidence and real-world use supported broader switching.

Revenue drivers that mattered commercially

• Access and net price: COPD inhaler economics in the US is net-driven. Rebates, copay assistance, and contract participation strongly influenced effective pricing.
• Adherence to device regimen: Pressurized inhaler technique and twice-daily cadence affected persistence, especially when competitors offered simpler schedules.

How do payer and provider dynamics affect Tudorza Pressair adoption in COPD maintenance?

Answer: Adoption has tracked formulary placement, prior authorization friction, and patient persistence on inhaler devices, with greatest headwinds when payers steer to once-daily LAMAs or fixed-dose LAMA/LABA combinations.

What payers typically do with LAMA choice

• Prefer preferred formulary tier options based on net cost and rebates.
• Use step edits that require trials of one or more inhalers before covering a second-line option.
• Apply quantity limits and device-eligibility rules in some plans, impacting persistence.

What providers typically do

• Physicians often switch to competitors when patients report:
  • Poor inhaler technique tolerance
  • Lack of perceived benefit after an adequate trial
  • Adherence issues due to dosing frequency

Which competitors most pressured Tudorza Pressair market share and pricing?

Answer: The main competitive pressure has come from established LAMAs (once-daily) and LAMA/LABA fixed combinations that improved convenience and symptom control for many patients.

Competitor set: class and regimen pressure

• Once-daily LAMAs: These compete directly on convenience and guideline alignment for maintenance therapy.
• LAMA/LABA fixed-dose combinations: These compete on efficacy and dosing simplicity, often positioned as next-step therapy.

Brand economics: how competition changes net revenue

When multiple LAMA and LAMA/LABA products vie for the same formulary slots, manufacturers typically respond with:

• Increased rebate pressure
• Copay support recalibration
• Contracting strategies tied to market share and outcomes

How does Tudorza Pressair dosing and device design influence persistence and switching?

Answer: Twice-daily dosing and Pressair device technique requirements increase the likelihood of non-persistence versus once-daily competitors, which can accelerate switching after coverage or affordability changes.

Device and adherence mechanics that drive outcomes

• Twice-daily dosing increases behavioral burden.
• If patient technique slips, effective delivered dose falls, which can lead to perceived underperformance and switching.
• Device education and reinforcement are resource-intensive, and gaps can erode persistence.

What is the financial impact of COPD guideline shifts on Tudorza Pressair?

Answer: As guidelines and payers moved toward simplifying regimens and using escalation pathways that emphasize once-daily and combination therapy, Tudorza’s relative advantage weakened.

Guideline and practice trend effects

• Step therapy: Patients often start with preferred agents and escalate to combination inhalers, leaving less room for a brand with less favored dosing.
• Combination positioning: LAMA/LABA products can absorb patients who would previously have stayed on a single LAMA.

When does Tudorza Pressair lose exclusivity, and what does that mean for revenue?

Answer: Revenue durability depends on the remaining lifespan of US Orange Book-listed patents and exclusivity periods, with the largest revenue shocks occurring around patent expirations and any successful or unsuccessful patent challenges that enable earlier generic entry.

What “loss of exclusivity” typically includes for inhalers

• Patent expirations: Composition, method-of-use, and formulation/device-related patents can extend effective exclusivity.
• Exclusivity protections: Statutory exclusivities tied to NDA approvals can add time in specific circumstances, though for mature inhalers the dominant factor is patent estate timing.

Revenue exposure from exclusivity cliffs

• Manufacturers with strong commercial footprints face:
  • Patient loss to lower net-cost generics
  • Rebate pressure that compresses net pricing
  • Margin and volume swings concentrated around generic launches

What patents protect aclidinium bromide in Tudorza Pressair, and how many are listed in the Orange Book?

Answer: A correct count and specific patent list requires Orange Book data for Tudorza Pressair’s application and dosage forms. Without a verifiable Orange Book listing set in the provided materials, an accurate, litigation-ready inventory of patents and expirations cannot be produced here.

What generic entry risks exist for Tudorza Pressair based on Paragraph IV challenges?

Answer: Paragraph IV risk is driven by active ANDA filings against listed Orange Book patents and the resulting litigation and settlement outcomes. A defensible risk view requires the ANDA Paragraph IV docket status tied to the exact NDA and patent numbers.

How does Tudorza Pressair compare with once-daily LAMAs on market dynamics?

Answer: Once-daily LAMAs generally have stronger commercial resilience because they align with payer and patient preferences for regimen simplicity, which affects persistence and switching rates.

Relative commercial positioning

• Tudorza’s twice-daily format creates a built-in disadvantage in competitive formulary negotiations.
• When formularies push simplification or preferred tier substitutions, the incremental value a twice-daily brand can offer is harder to defend.

What is the litigation and settlement landscape that could affect Tudorza Pressair exclusivity?

Answer: A litigation-ready map requires docket-specific information for ANDA Paragraph IV cases and any settlement agreements tied to specific Orange Book patents.

What is the FDA status of Tudorza Pressair (pathway, exclusivity, and labeling stability)?

Answer: A complete FDA regulatory status summary requires the specific NDA and labeling history and Orange Book exclusivity/patent linkages for Tudorza Pressair’s marketed strengths and dosage forms.

How should investors and licensors model unit share decline for Tudorza Pressair after generic entry?

Answer: Generic entry in COPD inhalers typically drives:

• Rapid share conversion driven by payer coverage and net price compression
• Persistent brand price pressure that can reduce volumes even before full conversion
• A “residual share” effect for patients stabilized on the device who face copay or adherence barriers shifting.

Key modeling inputs

• Pre-generic brand share and rebate structure
• Formulary aggressiveness at switch time
• Device interchangeability and patient retention
• Contracting dynamics for pharmacy benefit managers and large health systems

Is there a formulation or method-of-use strategy that could extend Tudorza Pressair’s financial life?

Answer: Brands can extend commercial life through line extensions, but the magnitude depends on whether line-extension patents withstand generic challenges and whether the new product maintains payer access. A precise assessment requires the specific continuation products and their patent estates.

Key takeaways

• Tudorza Pressair’s financial trajectory reflects structural COPD market pressures: twice-daily dosing disadvantage, payer steering toward once-daily LAMAs and LAMA/LABA combinations, and ongoing class rebate pressure.
• Exclusivity-driven revenue risk is the primary determinant of the endgame, with the timing and severity hinging on the specific Orange Book patent expirations and any Paragraph IV outcomes.
• Competitive dynamics in COPD inhalers are net-price and formulary driven, so share erosion can precede patent cliff events through contract design and preferred-tier swaps.

FAQs

1. How do formularies typically treat twice-daily COPD inhalers like Tudorza Pressair compared with once-daily LAMAs?
2. What happens to brand net pricing in US COPD inhalers immediately after generic LAMA or LAMA/LABA launches?
3. Do device-specific factors materially affect generic substitution and persistence for Pressair inhalers?
4. How can method-of-use or formulation patents influence generic entry timing for aclidinium bromide products?
5. What regulatory pathway and Orange Book linkages most affect exclusivity for inhaled COPD small molecules?

References

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (Drugs@FDA and Orange Book records for aclidinium bromide / Tudorza Pressair).
2. FDA Drugs@FDA database (Tudorza Pressair NDA records and labeling history).